BiotechTube

Inclisiran + Background lipid lowering therapy

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerotic Cardiovascular Disease

Conditions

Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol

Trial Timeline

Jul 7, 2021 → Jan 13, 2023

NCT ID
NCT04807400

About Inclisiran + Background lipid lowering therapy

Inclisiran + Background lipid lowering therapy is a phase 3 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04807400. Target conditions include Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved

Approved (8) Terminated (0) Active (12)
✅Rosuvamibe + MonorovaYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅atorvastatin + inclisiranNovartisApproved
✅InclisiranNovartisApproved
✅EvolocumabAmgenApproved
✅Placebo + EvolocumabAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04807400Phase 3Completed

Competing Products

20 competing products in Atherosclerotic Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
Rosuvamibe + MonorovaYuhanApproved
39
Rosuvamibe + MonorovaYuhanApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Placebo + AZD0780AstraZenecaPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
Epanova® (omega-3 carboxylic acids) + corn oil controlAstraZenecaPhase 3
40
atorvastatin + placeboMerckPhase 1
29
Anacetrapib + Placebo anacetrapibMerckPhase 3
44
Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + InclisiranNovartisPre-clinical
33
Ranolazine 500 mgNovartisPhase 2
27
Inclisiran + EvolocumabNovartisPhase 2
35
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5mlNovartisPhase 3
44
atorvastatin + inclisiranNovartisApproved
47
TQJ230 + PlaceboNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
44
PelacarsenNovartisPre-clinical
30
InclisiranNovartisPhase 3
40
InclisiranNovartisApproved
47
Pelacarsen (TQJ230)NovartisPhase 3
47